Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.30 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394048 | 0.80 | ALDH1A1 (0.51) | ALDH1A1GAATSHREPHX2TDP1 | |
| SCHEMBL939773 | 0.80 | ALDH1A1 (0.47) | ALDH1A1GAATSHRUSP2LMNA | |
| SCHEMBL612598 | 0.79 | TDP1 (0.34) | ALDH1A1GAATSHRTDP1 | |
| Hydrochloric Acid SCHEMBL612325 | 0.79 | ALDH1A1 (0.50) | ALDH1A1GAATSHREPHX2TDP1 | |
| SCHEMBL614902 | 0.75 | TDP1 (0.33) | ALDH1A1GAATDP1 | |
| SCHEMBL9341642 | 0.73 | ALDH1A1 (0.37) | ALDH1A1GAATSHREPHX2TDP1 | |
| SCHEMBL13481909 | 0.72 | ALDH1A1 (0.57) | ALDH1A1GAATSHRUSP2LMNA | |
| SCHEMBL6545165 | 0.72 | ALDH1A1 (0.38) | ALDH1A1GAATSHREPHX2TDP1 | |
| SCHEMBL1076980 | 0.71 | TSHR (0.39) | ALDH1A1GAATSHREPHX2TDP1 | |
| SCHEMBL626671 | 0.70 | TSHR (0.38) | ALDH1A1GAATSHREPHX2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010075520-A1 | PREPARATION OF GABAPENTIN ENACARBIL INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160666-A1 | PREPARATION OF GABAPENTIN ENACARBIL INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160666-A1 | PREPARATION OF GABAPENTIN ENACARBIL INTERMEDIATE | GABRB1, GABRB3, GABRB2 | ALDH1A1 1149/4885GAA 1413/4885TSHR 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.